I-Corps: Rapid Ultrasensitive Biodetection Chip for Early Lung Cancer Diagnosis

I-Corps：用于早期肺癌诊断的快速超灵敏生物检测芯片

• 批准号: 2309647
• 负责人: Donglei Emma Fan
• 金额: $ 5万
• 依托单位: University of Texas at Austin
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2309647&HistoricalAwards=false
• 关键词: Corps; Rapid; Ultrasensitive; Biodetection; Chip

The broader impact/commercial potential of this I-Corps project is the development of a rapid, ultrasensitive biomarker detection chip for applications in early lung cancer diagnosis. Lung cancer is the leading cause of cancerous deaths. This cancer claimed approximately 150,000 lives in the US in 2016, accounting for 25 percent of all cancer deaths. This disease is perilous due to the difficulties in its early-stage diagnosis and poor five-year survival rate (18%). Nevertheless, if detected early, the five-year survival rate can dramatically improve to 56%. Indeed, there is a dire need to develop user-friendly and low-cost, early-stage, lung-cancer diagnosis techniques based on simple body fluids, such as blood, saliva, and urine, for integration into regular wellness checks. In meeting this demand, this project seeks to develop a robust and portable cancer biomarker detection platform for early-stage lung cancer diagnosis from simple bodily fluids.This I-Corps project is based on the development of an on-chip lung-cancer biomarker detection platform. Currently, the use of biomarker sensing is intrinsically difficult for both ultra-sensitivity and high speed in detecting biomarkers in fluidic samples. To overcome this challenge, a light-pinpointed biomolecule concentrating technology that allows for simultaneous focusing and detection of biomarkers has been developed. The proposed technology may enable high fidelity and accuracy in diagnosing lung cancer at an early stage using simple bodily fluids, such as blood and saliva, during a regular wellness check. In addition, this diagnostic method may accelerate applications of nanobiosensing in practical, early-stage cancer diagnoses.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corps项目的更广泛的影响/商业潜力是开发快速，超敏感的生物标志物检测芯片，用于早期肺癌诊断中的应用。肺癌是癌变死亡的主要原因。该癌症在2016年在美国占有15万寿命，占所有癌症死亡的25％。由于其早期诊断和五年生存率较差（18％）的困难，这种疾病是危险的。然而，如果早期发现，五年的生存率可以显着提高到56％。的确，基于简单的体液（例如血液，唾液和尿液），需要开发用户友好和低成本的肺癌诊断技术，以整合到常规的健康检查中。在满足这一需求时，该项目旨在开发一个可从简单的身体流体的早期肺癌诊断的健壮且可移植的癌症生物标志物检测平台。该I-Corps项目基于开发片上芯片肺癌生物标志物检测平台。目前，对于超敏率和高速检测流体样品中的生物标志物，生物标志物传感的使用本质上是困难的。 为了克服这一挑战，已经开发了一种允许同时聚焦和检测生物标志物的轻夹点生物分子浓缩技术。 所提出的技术可以在常规健康检查中使用简单的体液（例如血液和唾液）在早期诊断肺癌的高保真度和准确性。 此外，这种诊断方法可能会加速纳米倍数在实用的早期癌症诊断中的应用。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子和更广泛影响的评估评估来获得支持的。